

Dear Editor,

thank you for your letter and the possibility to submit our revised opinion review titled “Exploring new treatment options for polycystic ovary syndrome - review of a novel antidiabetic agent SGLT2 inhibitor” by Jelena Marinkovic-Radosevic *et al.* for publication in the World Journal of Diabetes.

We have considered the reviewer’s and editor’s comments and revised the manuscript accordingly. We used the Track Changes to correct the manuscript.

*Reviewer #1: The reviewed manuscript is an Opinion Review on the possible role of SGLT-2 inhibitors in the treatment of polycystic ovary syndrome. Evidently, there are obvious application points for the mentioned class of antidiabetic drugs, although their mechanism of action are not direct. Current lack of evidence is correctly mentioned by the authors, as well as the need for further research. Conclusions are well-weighted and based on the provided data. I see no major flaws. My only minor recommendation is to use one type abbreviation throughout the text (for example SGLT-2i, or SGLT-2 inhibitors on the authors choice, as both are correct).*

We thank for this kind comment. We have corrected the manuscript accordingly and used the same abbreviation throughout the whole manuscript.

*Science editor: 5 Issues raised: (1) The key word “antidiabetic agents/diabetes” is missing in the title. Please add it; (2) Please provide the original figure documents.*

We add the key word in the title. We are submitting Figure 1 as a Power Point slide and assure that it is original.

We hope that we have improved the consistency and that the revised manuscript meets the requirements and is suitable for publication in *World Journal of Diabetes*.

Thank you again for the privilege of submitting our work to *World Journal of Diabetes*.

Sincerely,

Maja Cigrovski Berkovic, MD, PhD